GB2579179A — Cannabidiol-type cannabinoid compound
Assigned to GW Research Ltd · Expires 2020-06-17 · 6y expired
What this patent protects
Cannabidiol-C4 (CBD-C4, nor-cannabidiol) for use as a medicament is provided. CBD-C4 may be in the form of a plant extract, preferably in the form of a highly purified plant extract. The plant extract may comprise at least 95% (w/w) CBD-C4. CBD-C4 may be in the form of a syntheti…
USPTO Abstract
Cannabidiol-C4 (CBD-C4, nor-cannabidiol) for use as a medicament is provided. CBD-C4 may be in the form of a plant extract, preferably in the form of a highly purified plant extract. The plant extract may comprise at least 95% (w/w) CBD-C4. CBD-C4 may be in the form of a synthetic compound. A composition for use comprising CBD-C4 and one or more pharmaceutically acceptable excipients is provided. Cannabidiol-C4 for use in the treatment of epilepsy is provided. A process for the preparation of cannabidiol-C4 is provided.
Drugs covered by this patent
- Epidiolex (CANNABIDIOL) · Jazz Pharms Res
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.